Related Experiment Video
Updated: Apr 27, 2026

Measuring Naturally Acquired Phagocytosis-Inducing Antibodies to Plasmodium falciparum Parasites by a Flow Cytometry-Based Assay
Published on: August 6, 2020
Variation in the circumsporozoite protein of Plasmodium falciparum: vaccine development implications
Kavita Gandhi1, Mahamadou A Thera2, Drissa Coulibaly2
1Howard Hughes Medical Institute/Center for Vaccine Development, University of Maryland School of Medicine, Baltimore, Maryland, United States of America.
Insights
Malaria vaccine research explored Plasmodium falciparum circumsporozoite protein (CSP) diversity. No link was found between CSP genetic variation and malaria infection risk, suggesting immunity is not allele-specific.
Area of Science:
- Immunology
- Infectious Diseases
- Genetics
Background:
- The RTS,S/AS01 malaria vaccine targets Plasmodium falciparum circumsporozoite protein (CSP).
- Understanding the protective immune response to CSP remains a challenge.
- Polymorphisms in CSP may influence vaccine efficacy and natural immunity.
Purpose of the Study:
- To assess genetic diversity within immunogenic CSP regions.
- To investigate associations between CSP polymorphisms and malaria infection/disease risk.
- To inform future malaria vaccine development strategies.
Main Methods:
- Analysis of Plasmodium falciparum parasite samples from a Malian pediatric cohort.
- Sequencing of T-cell (Th2R, Th3R) and B-cell epitope regions of the CSP gene.
- Application of Cox proportional hazards models to evaluate sequence variation effects on infection incidence.
Main Results:
- CSP T-cell epitope regions showed stable diversity across seasons and infection types.
- A higher prevalence of 3D7 CSP haplotypes was observed in older children.
- No significant association was detected between CSP sequence variation and the risk of malaria infection or clinical disease.
Conclusions:
- Naturally acquired immunity to Plasmodium falciparum circumsporozoite protein may not be allele-specific.
- The study did not find evidence linking CSP genetic variation to protection against malaria.
- Further research is needed to elucidate the mechanisms of protective immunity against malaria.
Abstract:
The malaria vaccine candidate RTS,S/AS01 is based on immunogenic regions of Plasmodium falciparum circumsporozoite protein (CSP) from the 3D7 reference strain and has shown modest efficacy against clinical disease in African children. It remains unclear what aspect(s) of the immune response elicited by this vaccine are protective. The goals of this study were to measure diversity in immunogenic regions of CSP, and to identify associations between polymorphism in CSP and the risk of P. falciparum infection and clinical disease. The present study includes data and samples from a prospective cohort study designed to measure incidence of malaria infection and disease in children in Bandiagara, Mali. A total of 769 parasite-positive blood samples corresponding to both acute clinical malaria episodes and asymptomatic infections experienced by 100 children were included in the study. Non-synonymous SNP data were generated by 454 sequencing for the T-cell epitopes, and repeat length data were generated for the B-cell epitopes of the cs gene. Cox proportional hazards models were used to determine the effect of sequence variation in consecutive infections occurring within individuals on the time to new infection and new clinical malaria episode. Diversity in the T-cell epitope-encoding regions Th2R and Th3R remained stable throughout seasons, between age groups and between clinical and asymptomatic infections with the exception of a higher proportion of 3D7 haplotypes found in the oldest age group. No associations between sequence variation and hazard of infection or clinical malaria were detected. The lack of association between sequence variation and hazard of infection or clinical malaria suggests that naturally acquired immunity to CSP may not be allele-specific.
More Related Videos
08:46Myeloid Cell Isolation from Mouse Skin and Draining Lymph Node Following Intradermal Immunization with Live Attenuated Plasmodium Sporozoites
Published on: May 18, 2016
10:38High Yield Purification of Plasmodium falciparum Merozoites For Use in Opsonizing Antibody Assays
Published on: July 17, 2014
Related Concept Videos
Cross-reactivity
Vaccine Production
Diversity of Protists II
Vaccinations